NCT06613204 · Oregon Health and Science University
STELLA-FTD: Examination of a Behavior Change Intervention for FTD Family Care Partners
(STELLA-FTD)
What this study is about
The purpose of this nationwide study is to test STELLA-FTD (Support via Telehealth: Living and Learning with Advancing Alzheimer's Disease)-FTD, an intervention to specifically address the needs of family Care Partners of persons with frontotemporal degeneration (FTD).
View original scientific description
The purpose of this nationwide study is to test STELLA-FTD (Support via Telehealth: Living and Learning with Advancing Alzheimer's Disease)-FTD, an intervention to specifically address the needs of family Care Partners of persons with frontotemporal degeneration (FTD). STELLA-FTD is a multicomponent videoconference-based intervention designed to facilitate effective use of community and peer resources to foster effective management of behavioral and psychological symptoms of dementia. The study is recruiting families from across the United States.
Interventions
BEHAVIORAL
STELLA-FTD Control
Participants receive information about FTD and support via weekly group video-conference-based meetings.
BEHAVIORAL
STELLA-FTD Test
The test group receives a information and support, but with a focus that is different from the Control Group
Primary outcome measures
Revised Memory and Behavior Problems Checklist, Frequency, Original Scale
Time frame: 1 month pre-intervention; 1 week pre-intervention, 4 weeks after intervention start; 8 week post intervention; 2 and 6 months post intervention
Efficacy will be assessed by measuring pre/post changes on the RMBPC. The RMBPC is a 24-item caregiver report measure, 5-point Likert scale with higher scores on frequency indicate more upsetting behaviors Frequency range is 0 (never occurred) to 4 (daily or more often). Frequency score range is 0 to 96
Revised Memory and Behavior Problems Checklist, Reactivity, Original Scale
Time frame: 1 month pre-intervention; 1 week pre-intervention, 4 weeks after intervention start; 8 week post intervention; 2 and 6 months post intervention
Efficacy will be assessed by measuring pre/post changes on the RMBPC. The RMBPC is a 24-item caregiver report measure, 5-point Likert scale with higher scores on reactivity indicate more Care Partner burden. Frequency range is 0 (no burden) to 4 (high burden). Frequency score range is 0 to 96
Who can participate
This study lists these criteria on ClinicalTrials.gov. A study coordinator reviews eligibility during screening — this page does not determine whether you qualify.
Inclusion criteria
- Family Care Partner
- Adult caring for family member with FTD.
- Provides 4 or more hours of care/week. Does not have to reside with.
- Identifies at least 2 moderately upsetting behaviors in the person with FTD.
- Speaks and understands English to be able to participate in intervention.
- Owns a telephone (smartphone, cell phone or landline).
- Has email and mailing address to receive computer, study materials and surveys.
- Provides informed consent to participate in the research.
- Lives in the US Inclusion Criteria: Person with FTD
- Diagnosis of FTD
- Family member of a Care Partner (this can be a relative, spouse, or close kin that is considered family).
- Lives in US
Exclusion criteria
- Person with FTD
- No Frontotemporal Degeneration diagnosis.
- Unable to leave Care Partner during STELLA-FTD sessions.
- Enrolled in hospice. Exclusion Criteria: Family Care Partner
- Unable to find activity for Care Recipient during STELLA-FTD sessions to allow Care Partner to work privately with Guide and other Care Partners.
- Hearing and/or vision problems severe enough to prevent participation.
- Refuses to be video-recorded during STELLA-FTD sessions.
- Unwilling or unable to adequately follow study instructions and participate in study procedures.
Where
- Portland, Oregon
Collaborators
National Institute on Aging (NIA)
Related conditions & keywords
Frequently asked questions
What is a clinical trial?
A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.
Is it safe to participate?
Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.
Will I be compensated?
Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.
Will I receive a placebo instead of treatment?
When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.
Can I leave a trial if I change my mind?
Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.
How long does a clinical trial last?
Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.
Data: ClinicalTrials.gov · synced Oct 27, 2025 · Source of record for eligibility and locations